Live Breaking News & Updates on Treatment Satisfaction Questionnaire

Stay updated with breaking news from Treatment satisfaction questionnaire. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Depot Buprenorphine a Shot in the Arm for Opioid Addiction?

Depot Buprenorphine a Shot in the Arm for Opioid Addiction?
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

Wilsonm Compton , Norad Volkow , Fredrik Tiberg , National Institute On Drug Abuse , Medscape Medical , Treatment Satisfaction Questionnaire , National Institute , Drug Abuse , தேசிய நிறுவனம் ஆன் மருந்து , தேசிய நிறுவனம் ,

Long-Acting Opioid Use Disorder Treatment Brings Better Response

May 12, 2021
Patients report greater satisfaction with weekly, monthly buprenorphine
People with opioid dependence reported being more satisfied and more compliant with weekly or monthly depot buprenorphine versus sublingual buprenorphine, researchers reported.
In an open-label, 24-week randomized trial done at six outpatient clinical sites in Australia, the self-reported global satisfaction score was significantly higher for the depot group compared with the sublingual group at a mean TSQM (Treatment Satisfaction Questionnaire for Medication v1.4) score of 82.5 versus 74.3, for a difference of 8.2 (95% CI 1.7-14.6,
P=0.01), according to Fredrik Tiberg, PhD, of Camurus in Lund, Sweden, and co-authors (TQSM ranges from 0-100 with higher score indicating greater satisfaction). ....

United States , Plymouth Meeting , Shalmali Pal , Wilsonm Compton , Norad Volkow , Fredrik Tiberg , Braeburn Pharmaceuticals Camurus , Chiesi Pharmaceuticals , National Institute On Drug Abuse In Bethesda , Gw Pharmaceuticals , Janssen Pharmaceuticals , Treatment Satisfaction Questionnaire , Treatment Burden Questionnaire , National Institute , Drug Abuse , Substitution Treatment Qol , Patient Satisfaction Visual Analog Scale , Substance Use Recover Evaluator , Contributing Writer , ஒன்றுபட்டது மாநிலங்களில் , ப்லிமத் சந்தித்தல் , சிஐசி மருந்துகள் , தேசிய நிறுவனம் ஆன் மருந்து இல் பெதஸ்தா , க்வ் மருந்துகள் , ஜான்சன் மருந்துகள் , தேசிய நிறுவனம் ,

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence

Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
- Randomized, controlled study of Buvidal weekly and monthly subcutaneous depot injections vs daily sublingual buprenorphine
- The primary endpoint was met with statistically higher patient global satisfaction with the depot buprenorphine treatment
- Improved outcomes were also reported for secondary endpoints, including decreased treatment burden and higher quality of life
News provided by
Share this article
LUND, Sweden, May 10, 2021 /PRNewswire/ Camurus (NASDAQ STO: CAMX) announces today the publication in
JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly buprenorphine depot injections (Buvidal ....

New South Wales , Fredrik Joabsson , Peter Hjelmstr , Nicholas Lintzeris , Fredrik Tiberg , United Nations , University Of Sydney , Business Development , Depot Evaluation , Utilization Trial , Professor Nicholas Lintzeris , Conjoint Professor , Addiction Medicine , Treatment Satisfaction Questionnaire , Chief Medical Officer , Reported Outcomes , Opioid Dependence , Monthly Subcutaneous Depot , Daily Sublingual Buprenorphine , Randomized Clinical , Product Characteristics , Australian Product , Buvidal Weekly , European Medical Agency , Medical Products , Human Use ,

Camurus : 2021-05-10 Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence

PRESS RELEASE
Camurus announces publication showing superior patient treatment satisfaction with Buvidal® weekly and monthly depot injections in opioid dependence
Randomized, controlled study of Buvidal weekly and monthly subcutaneous depot injections vs daily sublingual buprenorphine
The primary endpoint was met with statistically higher patient global satisfaction with the depot buprenorphine treatment
Improved outcomes were also reported for secondary endpoints, including decreased treatment burden and higher quality of life
Lund, Sweden - 10 May 2021 - Camurus (NASDAQ STO: CAMX) announces today the publication in JAMA Network Open of results from a 24-week, randomized, controlled trial (DEBUT) comparing patient reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly buprenorphine depot injections (Buvidal®) versus daily sublingual buprenorphine. ....

Fredrik Joabsson , Fredrik Tiberg , Buvidal Weeklyand , United Nations , Business Development , Depot Evaluation , Utilisation Trial , Treatment Satisfaction Questionnaire , Product Characteristics , Australian Product , European Medical Agency , Medical Products , Human Use , Nasdaq Stockholm , Reported Outcomes , Opioid Dependence With Weekly , Monthly Subcutaneous Depot , Daily Sublingual , Randomized Clinical , Drug Report , Chief Business Development Officer , ஒன்றுபட்டது நாடுகள் , வணிக வளர்ச்சி , டிப்போ மதிப்பீடு , ப்ராடக்ட் பண்புகள் , ஆஸ்திரேலிய ப்ராடக்ட் ,